Müller, Britta
Gaul, Charly
Reis, Olaf
Jürgens, Tim P.
Kropp, Peter
Ruscheweyh, Ruth
Straube, Andreas
Brähler, Elmar
Förderreuther, Stefanie
Schroth, Jennifer
Dresler, Thomas
Article History
Received: 2 February 2023
Accepted: 9 March 2023
First Online: 4 April 2023
Declarations
:
: The Ethics Committee of the Faculty of Medicine, University of Leipzig reviewed and approved the study (297/16-ek). All participants gave their written informed consent.
: Charly Gaul received honoraria for consulting and lectures within the past three years from Allergan/AbbVie, Lilly, Novartis Pharma, Hormosan Pharma, Grünenthal, Sanofi-Aventis, Weber & Weber, Lundbeck, Perfood, and TEVA. His research is supported by a grant of the German Research Foundation (DFG). He does not hold any stocks of pharmaceutical companies. He is honorary secretary of the German Migraine and Headache Society. Tim P. Jürgens has served on advisory boards and/or has received honoraria for lectures from Alleregan, Grünethal, Hormosan, Lilly, Lundbeck, Novartis, Sanofi, and TEVA. Peter Kropp has received funding from Takeda, travel- and lecture fees from Novartis, Lilly, and Teva. Ruth Ruscheweyh has received travel grants and/or honoraria from Allergan/AbbVie, Hormosan, Lilly, Novartis and Teva. Andreas Straube has received honoraria for lectures and consultations within the past 3 years from Allergan, Allergosan, Bayer, Lilly, Novartis, Teva. Stefanie Förderreuther has received honoraria for lectures and consultations within the past 3 years from Allergan, Hormosan, Lilly, Novartis, Sanofi, TEVA. Thomas Dresler has received honoraria for consulting and lectures within the past 3 years from Hormosan Pharma, Novartis Pharma, and TEVA. Elmar Brähler, Britta Müller, Olaf Reis, and Jennifer Schroth declare that they have nothing to disclose.